knowledge -WSS

knowledge

author：focus 2025-08-25 16:33:51 - browse：969

ANDREW YATES/AFP via Getty Images

WASHINGTON — A federal judge in Delaware on Friday ruled against AstraZeneca in a case challenging the constitutionality of Medicare’s new drug price negotiation program.

Colm Connolly, chief judge of the U.S. District Court of Delaware, ruled against the company on all its major arguments. He wrote that AstraZeneca had not proved that Medicare’s new drug price negotiation program jeopardizes its constitutional property rights, and that the company didn’t have standing to challenge the guidance Medicare issued to implement the program.

The case is the first of a slew of cases filed by the pharmaceutical industry and its allies to be decided at the district court level. The Delaware ruling is a blow, as several of the other cases made similar arguments about how the program violates drugmakers’ constitutional property rights.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Ripples from Flovent's discontinuation is killing children with asthma

focus

entertainment

WSS

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Obesity drug from Roche shows promise in early study

How to make the FDA’s new prescription one

Boston hospital trains restaurant workers on naloxone for overdoses

ALS treatment from Biogen, Ionis fails in study

Fertility clinic egg and embryo storage is a disaster

knowledge

knowledge

focus

Guidelines to prevent youth baseball injuries need more muscle

As H5N1 spreads in cows, experts warn against drinking raw milk

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FDA panel endorses Alnylam’s heart drug — after picking it apart

George Santos makes 1st court appearance after pleading not guilty to 13 counts

The United States must get value

Novavax promises a turnaround & Lilly roils the obesity market

Boston hospital trains restaurant workers on naloxone for overdoses

Drug repurposing or repositioning? The language matters

Will the IRA bring competition to the biologics market?

explore

Lilly’s weekly insulin works as well as daily products, new studies show

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

New weight loss drugs vying to be the next Wegovy or Mounjaro

Hospitals consider fixing cancer drug shortages on their own

Long Covid needs a new name — and a new frame

Will the IRA bring competition to the biologics market?

Wikipedia

focus

entertainment

knowledge